摘要
目的:观察慢性乙型肝炎(CHB)患者中HBV基因型分布及其临床意义。方法:应用荧光PCR技术对27例CHB患者进行HBV基因型分析,所有患者均采用拉夫米定治疗12个月,观察患者病毒学应答率、血清学应答率和生化学应答率。结果:在27例CHB患者以B、C基因型为主,分别占22.2%和66.6%。汉族和维吾尔族患者基因型分布差异有显著性意义(P<0.001)。C基因型在As C、CHB、LC和HCC分别占50.0%、58.3%、85.7%、100%,C基因型患者随着慢性肝病的病情加重所占比重加大。B基因型患者在3个月病毒学应答率上均显著优于C基因型。结论:C基因型是CHB患者的主要基因亚型,且与患者疾病进程有关,B基因型患者对拉夫米定抗病毒疗效优于C基因型。
Objective： To investigate the HBV genotype distribution of chronic hepatitis B patients and its clinical significance. Methods： Twenty-seven patients with chronic hepatitis B were detected HBV genotype by using fluorescent PCR technique. All patients were treated with lamivudine for 12 months and observed virologic response rates,serological response rates and biochemical response rates. Results：B genotype and C genotype accounted for 22. 2% and 66. 6% respectively in the 27 cases. There was significant difference（ P〈0. 001） between the Han and Uygur on HBV genotype. C genotype took more and more proportion with chronic hepatitis disease gradually increase. In the third months virologic response rate of B genotype patients was significantly better than C genotype patients. Conclusion： C genotype was a major genotype model of chronic hepatitis B patients,and significantly associated with the disease process,meanwhile,the antiviral efficacy of lamivudine in B genotype patients was more effective than C genotype.
出处
《中西医结合肝病杂志》
CAS
2015年第3期147-149,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
新疆兵团重大科技计划发展项目(No.2013AB028)
关键词
肝炎
乙型
慢性
基因型
拉夫米定/治疗应用
疗效
hepatitis B
chronic
genotype
lamivudine / therapeutic epplication
therapeutic effect
